Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
Article in Chinese | WPRIM | ID: wpr-958546

ABSTRACT

Objective:To explore safe dosage of single intravitreal injection of ganciclovir (IVG) in healthy rabit eyes, and to explore retinal toxicity of different dosage of ganciclovir after continues intravitreal injection into the vitreous cavity of healthy albino rabbit eyes.Methods:Ten healthy New Zealand albino rabbits were divided into 5 groups with 2 rabbits in each group. Each group was injected with 1 mg/0.025 ml,2 mg/0.025 ml, 5 mg/0.025 ml, 10 mg/0.025 ml ganciclovir or 0.025 ml saline (control group). After 1 week of intervention, rabbits were examined by ultra-wide-angle fundus photography, optical coherence tomography (OCT) and full field electroretinogram (ERG). The maximum mixed response of rod and cone cells (Max-R) was measured under dark adaption conditions, cone response (Cone-R) and 30 Hz flicker response (30 Hz-R) were measured under light adaption conditions. Twenty-four healthy New Zealand albino rabbits were randomly divided into a low-dose experimental group, a low-dose control group, a high-dose experimental group, and a high-dose control group, with 6 rabbits in each group, with the right eye as the experimental eye. The rabbits in the high-dose experimental group were continuously injected with ganciclovir 2 mg/0.025 ml, once a week, for a total of 4 times. The rabbits in the low-dose experimental group were injected with 1 mg/0.025 ml ganciclovir, the induction period was 2 times/week, a total of 4 times; the maintenance period was 1 time/week, a total of 2 times. The rabbits in the high-dose control group and the low-dose control group were injected with 0.025 ml normal saline into the vitreous cavity respectively. Full-field ERG examination was performed 1 day before each injection and 1 week after the last injection. Max-R was measured under dark-adapted conditions, and Cone-R and 30 Hz-R were measured under light-adapted conditions. OCT was recorded before the first injection and one week after the last injection. One week after the last injection, the experimental rabbits in each group were sacrificed for hematoxylin-eosin staining, and the retinal structure was observed under a light microscope. The comparison of a-wave and b-wave amplitude of Max-R, Cone-R and 30 Hz-R amplitude at different time was performed by two independent sample nonparametric test.Results:There were no abnormal results of fundus photography, OCT and ERG after single intravitral injection of 1 mg or 2 mg ganciclovir. One week after single 5 mg IVG, fundus photography of rabbits showed vascular occlusion and preretinal hemorrhage and ERG showed slight decrease of amplitude of Max-R, Cone-R and 30 Hz-R. One week after single 10 mg IVG, retinal necrosis and exudative changes were also observed. OCT showed edema and unclear retinal structure in the necrotic area. ERG showed significant decrease of amplitude of Max-R, Cone-R and 30 Hz-R. After continuous IVG in high dose and low-dose experimental group, the amplitude of Max-R a wave ( Z=-0.160, 0.000) and b wave ( Z=-0.321, 0.000), Cone-R a wave ( Z=-0.641,-0.641) and b wave ( Z=-0.321, -0.160), and 30 Hz-R ( Z=-0.321,-0.160) showed no difference compared to control group. No histologic evidences of retinal microstructure abnormalities were found in both groups. OCT and fundus photography before and after the intervention did not show any difference, either. Conclusion:There was no retinal toxicity of continuous 1 mg or 2 mg IVG recorded in albino rabbits.

2.
Article in Chinese | WPRIM | ID: wpr-868573

ABSTRACT

Objective To define the maximum-tolerated dose (MTD) of lobaplatin (LBP) in a weekly regimen combined with concurrent radiotherapy in the treatment of locally advanced nasopharyngeal carcinoma (NPC).Methods A total of 18 cases with stage Ⅲ/Ⅳ A NPC were enrolled.Concurrent chemoradiotherapy was given to all the patients with a dose escalation of LBP.The initial dose of LBP was 15 mg/m2 with an escalating dose of 5 mg/m2.At least 3 patients were assigned into each group.Patients were proceeded into the next dose group if no dose-limiting toxicity (DLT) occurred until the MTD was achieved.Efficacy and toxicity were evaluated regularly.Results Three patients were assigned into the 10 mg/m2,3 into the 15 mg/m2,and 6 into the 20 mg/m2 and 25 mg/m2 groups,respectively.Two patients experienced DLT in the 25 mg/m2 group.Hence,the MTD was determined as 20 mg/m2.At 3 months after corresponding treatment,the remission rate of nasopharyngeal tumors and neck-positive lymph nodes of the patients was 100%.The most common toxicity was reversible bone marrow suppression.Conclusions The MTD of weekly lobaplatin plus concurrent IMRT is 20 mg/m2 for locally advanced NPC.This regimen is reliable and safe,which is worthy of further clinical study.

3.
Article in Chinese | WPRIM | ID: wpr-855827

ABSTRACT

AIM: To introduce a novel and flexible model-assisted design for Phase I clinical trials: Bayesian optimal interval (BOIN) design, including the process of implementation, practical implementation, and evaluation of its performance. METHODS: BOIN design decides dose escalation/de-escalation by comparing the observed toxicity rate at the current dose with an escalation boundary and a de-escalation boundary that are optimized to minimize the probability of making incorrect decision of dose assignment. The application of the BOIN design is illustrated using a trial example. RESULTS: BOIN combines the advantages of the algorithm-based methods and model-based methods. It enjoys desirable statistical properties -it is optimal, safe, robust and easy to implement. Simulation study shows that the BOIN substantially outperforms the existing designs with higher accuracy to identify the maximum tolerated dose (MTD). CONCLUSION: BOIN design possesses the similar statistical performance to the much more complicated model-based designs. It is simple to implement, and easy to calibrate to meet the safety requirement mandated by regulatory agents. The BOIN design has been widely used in different types of cancers. It is a novel design that holds great potential to substantially improve phase I trials in China.

4.
China Pharmacy ; (12): 1237-1241, 2018.
Article in Chinese | WPRIM | ID: wpr-704772

ABSTRACT

OBJECTIVE:To establish the quality standard of Hirudo nipponica freeze-dried powder(called"freeze-dried powder"for short),and to provide reference for controlling its quality. METHODS:A total of 3 batches of freeze-dried powder were collected,identified and tested according to the requirements of H. nipponica stated in 2015 edition of Chinese Pharmacopoeia(part Ⅰ)(shorted for pharmacopoeia);the antithrombin activity was also analyzed. The maximum tolerated dose (MTD)was used to investigate the toxicity. The stability was determined by designing temperature,humidity and strong light exposure tests. RESULTS:In the TLC of test sample,the same red spots were found in the corresponding location of the control drug chromatogram,and the same orange-red fluorescence spots were shown under the UV light(365 nm). Average content of moisture in 3 batches of samples was 2.61%,and the levels of total ash,acid-insoluble ash,pH aflatoxin and antithrombin activity were 2.83%,0.38%,6.92,0.28 μg/kg and 257.0 U/g,respectively. The content of Pb,Cd,As and Cu were in line with the requirements of pharmacopoeia except that the content of Hg was slightly higher than lower limit of H. nipponica in pharmacopoeia. Results of MTD showed that no death and ADR was found in mice after giving 26.4 g/kg freeze-dried powder by the amount of crude drug,which was 58 times as large as the maximum dosage that the pharmacopoeia described. Under the condition of 20, 40 ℃ and strong light exposure [(4 500±500)Lx],the anticoagulase activity of freeze-dried powder decreased significantly over time,while the anticoagulase activity of freeze-dried powder stored at 40 ℃ for 6 months was in line with the requirements of pharmacopoeia. Under the condition of high humidity(relative humidity were 90%,75%),freeze-dried powder showed a strong hygroscopicity. CONCLUSIONS:Established quality evaluation standard for freeze-dried powder according to pharmacopoeia standard could be used to control its quality.

5.
Article in English | WPRIM | ID: wpr-163707

ABSTRACT

OBJECTIVE: This phase I study aimed to determine the maximum tolerated dose (MTD) of Genexol-PM, when combined with carboplatin, as a first-line treatment in patients with advanced ovarian cancer. METHODS: This open-label, multicenter, phase I, dose-escalation study included 18 patients (median age: 59.0 years, range: 40–75 years) diagnosed with advanced epithelial ovarian cancer. All patients had measurable residual disease after debulking surgery. Patients were assigned to groups (n=6 each group) that received different doses of Genexol-PM (220, 260, and 300 mg/m², once every 3 weeks) and 5 area under the curve (AUC) carboplatin. Safety and efficacy were analyzed for each dose group. RESULTS: In this intention-to-treat population, 3 out of 18 patients dropped out of the study: 1 due to dose-limiting toxicity (DLT), 1 due to hypersensitivity, and 1 was lost during follow-up. DLTs were not reported at 220 mg/m² or 260 mg/m², but at 300 mg/m², 1 patient experienced DLT (grade 3 general pain). The MTD of Genexol-PM was not determined, but a dose of 300 mg/m² or less could be recommended for the phase II study. Most patients (73.9%) with adverse events recovered without sequelae, and no death occurred that was related to the disease or treatment. The best overall response rate was 94.1%. CONCLUSION: Genexol-PM combined with carboplatin was well tolerated as a first-line treatment, and good responses were observed in patients with advanced ovarian cancer. Based on these results, we recommended a dose of 300 mg/m² or less for a phase II study.


Subject(s)
Humans , Carboplatin , Follow-Up Studies , Hypersensitivity , Maximum Tolerated Dose , Ovarian Neoplasms , Paclitaxel , Polymers , Toxicity Tests
6.
Article in Chinese | WPRIM | ID: wpr-496854

ABSTRACT

Objective To discuss the maximum tolerated dose of oxaliplatin based on 5-fluorouracil derivative in patients with locally advanced rectal cancer who underwent neoadjuvant chemoradiotherapy.Methods From Mar 2015 to Oct 2015,15 locally advanced rectal cancer patients (T3,T4/N +) who received intensity modulated radiotherapy and concurrent chemotherapy with capecitabine and oxaliplatin were enrolled in this study.The prescription dose was 50.6 Gy for gross tumor volume(GTV) and 41.8 Gy for clinical tumor volume(CTV) in 22 fractions within 30 d with concomitant boost.There were four dose-level groups of oxaliplatin as 100,110,120 and 130 mg/m2 tri-weekly and fixed capecitabine dose (825 mg/m2 bid d1-5 per week).The first 12 patients were randomly assigned into 4 groups.For the 130 mg/m3 group,another 3 patients were enrolled because of dose-limiting toxicity (DLT).Treatment related toxicities and response rates were evaluated.Results The most common adverse events(AE) were radiation enteritis,skin reactions,nausea,fatigue,urinary system AE and bone marrow suppression.There was a trend of increase by the dose level of oxaliplatin for toxicities.Groups 100,110 and 120 mg/m2 had none DLT,while group 130 mg/m2 had 1 patient for grade 3 thrombopenia and 1 patient for grade 3 nausea.Postoperative pathology showed that all patients achieved tumor downstaging,among which 0,1,2,3 cases achieved complete remission of the four groups,respectively.Conclusions The combination regimen of capecitabine and oxaliplatin is safe and effective according to the preliminary results.The maximum tolerated dose of oxaliplatin was 130 mg/m2 tri-weekly.

7.
Chinese Pharmaceutical Journal ; (24): 1785-1788, 2014.
Article in Chinese | WPRIM | ID: wpr-860144

ABSTRACT

OBJECTIVE: To discuss early exploratory bridging studies between early screening phase and pivotal general toxicology studies and their application during new drug development. METHODS: The opinions on acute toxicity study from international counterparts and current application in domestic and overseas were briefly reviewed. At the same time, the study design and the strengths of an alternative maximum tolerated dose /dose range finding (MTD/DRF) study widely used abroad were fully discussed. Furthermore, considerations were also highlighted based on the authors' experience, which may aid in the design and the conduct of such bridging studies. RESULTS AND CONCLUSION: MTD/DRF study could provide more valuable information for subsequent non-clinical regulatory toxicity studies. It is a rational and practical general toxicological study with bridging character.

8.
Herald of Medicine ; (12): 721-722, 2014.
Article in Chinese | WPRIM | ID: wpr-452038

ABSTRACT

Methods The maximum tolerated dose( MTD)of water and ethanol extracts of Radix millettiae speciosae were measured for the safety evaluation. Results Maximal tolerated dose( MTD)of water extract was higher than 1 000 g·kg-1 ,which equaled to 110 times the dose for human adults(60 kg). MTD of ethanol extract was higher than 1 700 g·kg-1 ,which equaled to 186 times the dose for human adults(60 kg). Conclusion Radix millettiae speciosae does not have obvious toxicity,thus its routine clinical dose is safe and feasible.

9.
Chinese Pharmaceutical Journal ; (24): 446-449, 2013.
Article in Chinese | WPRIM | ID: wpr-860444

ABSTRACT

OBJECTIVE: To prepare the paclitaxel liposomes and evaluate its physicochemical property, toxicity and pharmacodynamics. METHODS: SPC, mPEG2000-DSPE and paclitaxel were dissolved in chloroform in a mole ratio of 100:0.5:5. Oil phase and water phase were mixed and skived. The emulsion was homogenized to form liposomes. The mean diameter of liposomes was determined by dynamic light scattering (DLS) techniques. Low-speed centrifugation was employed to determine encapsulation efficiency (EE). The maximum tolerated doses (MTD) was determined in normal KM mice, and antitumor effect was evaluated in H22/KM mice xenograft tumor model. RESULTS: The mean diameter of paclitaxel liposomes was (140±10) nm. The EE was over 95% when the molar ratio of paclitaxel to SPC ranged from 3% to 6%. The MTDs of Pac-lipo and Pac-free in male KM mice were 64.8 and 29.4 mg · kg-1, respectively. Pac-lipo inhibited H22tumor weight dose-dependently. CONCLUSION: Pac-lipo had a high EE, and could increase the therapeutic index significantly, compared with Pac-free.

10.
Article in Chinese | WPRIM | ID: wpr-855164

ABSTRACT

Objective: To research the toxicity variation principle of "pinellia, trichosanthes, fritillaria, ampelopsis, bletilla attack aconitum" through studying on the acute toxicity for "pinellia, trichosanthes, fritillaria, ampelopsis, bletilla attack aconitum" in the single herb and anti-drug combination. Methods: Using the median lethal dose (LD50) or maximum tolerate dose (MTD) to evaluate the acute toxicity of single herb, then fix the raw aconitum dose of the compatibility group at LD50, another drug dose increased with the compatibility proportion changed gradually in order to examine the toxicity variation of anti-drug combination with death rate as the index. Results: The LD50 of raw Aconiti Radix (AR) was 4.4 g/kg, the MTD of raw Pinelliae Rhizoma (PR), Trichosanthis Fructus (TF), Fritillariae Thunbergii Bulbus (FTB), Ampelopsis Radix (AR), and Bletillae Rhizoma (BR) was respective 300, 37.8, 272, 167, and 180 g/kg; raw AR and raw PR showed no antagonism phenomenon; raw AR showed the antagonism effect against TF in 4:1 to 8:1 while without antagonism in 2:1-1:6; the compatibility of raw AR and FTB objected in 6:1-16:1 while without antagonism in 1:1-1:13; the compatibility of raw AR and AR objected in 3.5:1-16:1 while without antagonism in 1:1-1:13; the compatibility of raw AR and BR showed no obvious toxicity variation. Conclusion: The ethanol extract of raw AR has obvious acute toxicity; the ethanol extract of raw PR, TF, FTB, AR, and BR has no obvious acute toxicity; under the experimental conditions, the proportion of anti-drug compatibility affects the compatibility of the results.

11.
Article in Chinese | WPRIM | ID: wpr-417839

ABSTRACT

ObjectiveTo define the maximum tolerated dose (MTD) of weekly cisplatin in concurrent chemoradiotherapy for Chinese cervical carcinoma.MethodsCervical carcinoma of stage ⅠB2- ⅣA were eligible for the study.PhaseⅠstudy was dose-escalation trial with 15 patients.All patients received whole pelvic radiotherapy with three dimentional conformal radiotherapy technique. Concurrent cisplatin started from the dose of 20 mg/m2 to 25 mg/m2,30 mg/m2,35 mg/m2,40 mg/m2 for the weekly schedule ( ≥3 patients per dose group) and the doses were steadily escalated to 40 mg/.m2.If the dose was increased to 40 mg/m2 without dose-limiting toxicity ( DLT),40 mg/m2 would be the maximum tolerated dose (MTD).According to the MTD dose from Phase Ⅰ study,we conducted phase Ⅱ clinical trial with 36 patients.ResultsIn Phase Ⅰ study,cisplatin dose was escalated to 40 mg/m2 and DLT had not been reached.Thirty-six patients in Phase Ⅱ study included 9 inpatients and 27 outpatients.All 9 inpatients completed 6 cycles of chemotherapy. In 27 outpatients,18 patients (66%) completed 6 cycles of chemotherapy,19 patients (70%) completed 5 cycles and 25 patients (92%) completed 4 cycles of chemotherapy.All patients completed radiotherapy.Major adverse effects were grade 1 and 2 gastrointestinal toxicities and neutropenia.ConclusionsWeekly 40 mg/m2 cisplatin concurrent with radiotherapy is well tolerated when given to Chinese patients with cervical carcinoma. For outpatients with poor performance status,the cisplatin dose needs to be reduced.

12.
Article in Chinese | WPRIM | ID: wpr-414439

ABSTRACT

Objective Inaccurate dosing is an important cause of medical malpractice, how to adjust the medication dose to overcome the excessive deviation will be discussed in this paper. Methods Gold zone method was proposed on the basis of the probability theory and mathematical statistics for handling inaccurate dosing problems. Investigation and study in large sample size was carried out on adverse reactions of Cefamandole Nafate for Injection by adopting the method. Results The conclusions from the super large sample size test indicate that there is highly significant difference of total adverse reaction rates between taking values within and outside golden zone of dosage, and the adverse reaction rate of taking values within golden zone is significantly lower than that of outside golden zone. It is noteworthy that when dosage was lower than golden zone,the adverse reaction rate was significantly increased,which is more than 4 times of that within golden zone. Conclusion It is effective measures and simply and easy to apply that taking values within golden zone of dosage reduce adverse drug reactions,probability within golden zone less than 1/4 range of experience that contains the actual demand of the body up to 70%.

13.
Article in Chinese | WPRIM | ID: wpr-386001

ABSTRACT

Objective To investigate the acute toxicity of intravenous isoflurane in Beagles.Methods Six healthy adult Beagles of both sexes aged 6-8 months weighing 6-8 kg were used in this study.Isoflurane injectio (120 mg/ml) in 30% hpid emulsion was injected intravenously. Femoral artery was cannulated for direct BP monitoring.ECG was continuously monitored.The maximal tolerance dose (MTD) and approximate lethal dose (ALD) were determined by up-and-down technique. The initial dose was 3.0 ml/kg. The dose was decreased/increased by 0.3 ml/kg if the previous animal died/survived.The survived dogs were observed for 2 weeks.Autopsy and histopathological examination were performed on all dead Beagles.Results The ALD and MTD of intravenous isoflurane were 252 and 216 mg/kg. Autopsy and histopathological examination did not show any abnormality.Conclusion Cardiopulmonary depression is the main manifestation of the acute toxicity of intravenous isoflurane in Beagles.

14.
Article in Chinese | WPRIM | ID: wpr-398410

ABSTRACT

Objectives To determine maximal tolerated dose(MTD)and dose-limiting toxicity (DLT) of oxaliplatin(L-OHP)when combined with constant dosing of 5-Fu、Lv and concurrent radiotherapy in postoperative patients with rectal cancer.Methods A total of 21 patients with stage Ⅱ or Ⅲ rectal adenocarcinoma after curative surgery were treated with radiotherapy to a total dose of 50 Gy in 5 weeks.L-OHP was administered at a dosge of 45 mg/m2(n=3),55 mg/m2(n=3),65 mg/m2(n=3),75 mg/m2(n=6),and 85 mg/m2(n=6)once a week for 2 weeks(first cycle)followed by a second cycle after a 14-day break.5-Fu and LV at a fixed dose of 5-Fu 300 mg/m2 ivdrip for 2 h,then 500 mg/m2 ivdrip within 22 h,d1,d2.LV 200 mg/m2 ivdrip 2 h d1,d2.DLT was defined as grade Ⅲ or Ⅳ hematologic and nonhenmologic toxicity. Results Grade Ⅰ-Ⅲ leukopenia,diarrhea,and nausea/vomiting were the most common toxic side effects.and most were of grade 1-2.DLT was first observed in 2 of 3 patients at 75 mg/m2(1 of grade Ⅲ diarrhea and 1 of grade Ⅲ leukopenia).L-OHP at dosage of 85 mg/m2 caused DLT in 4 of 6 patients(2 of grade Ⅲ leukopenia and 1 of grade Ⅲ diarrhea and 1 of grade Ⅲ diarrhea).Conclusions Diarrhea was the most common dose-limiting toxicity(DLT).Tlle maximal tolerated dose(MTD)of L-OHP in this setting was 75 mg/m2 which was comparable to the maximal tolerated dose of L-OHP seen in the neoadjuvant setting.

15.
Article in Chinese | WPRIM | ID: wpr-401476

ABSTRACT

Objective A phase Ⅰ study was conducted to determine the maximal tolerated dose (MTD) and the dose-limiting toxicity(DLT) of chemotherapy of oral doxifluridine(5-dFUR) and leucovorin with concurrent standard radiotherapy(RT) as adjuvant treatment in patients with rectal cancer. Methods Patients aged 18-75 years old, Karnofsky scored ≥70%, stage Ⅱ/Ⅲ rectal cancer after curative surgery were eligible. Total RT dose was delivered as DT 50 Gy in the fraction of 2.0 Gy per day for 5 weeks to the pelvic area. 5-dFUR was administered concurrently with radiotherapy in escalating doses, and oral leucovorin was The DLTs included grade 3 or grade 4 hematologic and nonhematologic toxicity. Results From Aug. 2005 the most common side effects although all neutropenia was less grade 3. The DLT was observed in 1 patient of RT. In the following 3 enrolled patients, one suffered grade 3 abdominal cramp pain, diarrhea, fatigue, nausea/vomit and grade 2 neutropinea and fever. Grade 3 diarrhea was also observed in all the additional 3 papatients didn't complete the scheduled concurrent chemoradiotherapy due to severe side effects,including 1 at grade 3 abdominal cramp pain,fatigue and nausea/vomit. Conclusions Diarrhea is the most common and severe side effect in this phase Ⅰ study. The MTD of doxifluridine, concurrently with RT and fixed dose of oral cramp pain is often accompanied with diarrhea and nauser/vomit when the dose of doxifluridine exceeds 550 mg/( m2 · d) or 900 mg/d,patients need to be observed carefully.

16.
China Pharmacy ; (12)2007.
Article in Chinese | WPRIM | ID: wpr-531219

ABSTRACT

OBJECTIVE:To observe the clinical efficacy,safety,the maximal tolerated dose(MTD) and dose-limiting toxicity(DLT) of docetaxel(TXT) in the treatment advanced breast cancer.METHODS:Docetaxel was given by drip infusion in escalating doses from the initial dose of 65 mg?m-2 to 75 mg?m-2 and 85 mg?m-2 until the appearance of DLT.RESULTS:Among the 15 cases,1 case with CR,5 PR,4 SD,and 5 PD.The DLT of TXT was neutropenia,and its MTD was 85 mg?m-2.CONCLUSION:Docetaxel(at a dose of 75 mg?m-2) showed remarkable efficacy and good tolerance in patietns with advanced breast cancer.

17.
China Oncology ; (12)2001.
Article in Chinese | WPRIM | ID: wpr-539829

ABSTRACT

Purpose:The phase I study was conducted to evaluate the maximum tolerated dose (MTD) and toxicity of weekly administered docetaxel combined with cisplatin in patients with non-small cell lung cancer ( NSCLC ). The other objective was to measure the pharmacokinetic/dynamics (PK/PD).Methods:In the dose escalation study, 15 patients with unresectable and metastatic untreated NSCLC with performance status(0-1) were enrolled. Escalating doses of D 25 mg/m 2 (30 mg/m 2, 35 mg/m 2, 40 mg/m 2) on day 1, 8, 15 were given as a 30 min iv infusions and C 75 mg/m 2 30 min iv infusion after D on day 1 and the cycle was repeated every 4 weeks. Blood samples were drawn on day 1 and 15 in the first cycle to measure the PK. Dose limiting toxicity(DLT) was based on Cycle 1 and defined as any Grade 3 non-hematologic toxicity not declining to Grade 2 or less within 4 days or any Grade 4 toxicity. Results:Chemotherapy was repeated for at least two cyc1es every 28 days. All patients were assessable for toxicities. Although grade 3/4 neutropenia occurred, there were no significant modifications of chemotherapy schedule. One patient developed an infection (DLT). Non-hematological toxicities, including nausea/vomiting, a1opecia, fluid intension and asthenia were tolerable. Based on these data, the MTD has not yet reached up to dose level of docetaxel of 40mg/m 2 weekly given in combination with cisplatin 75mg/m 2 every 4 weeks at the fixed dose. The exposure to docetaxel after Ⅳ administration on day 1 in combination with cisplatin and on day 15 without cisplatin , increased proportional to the dose for the range 25 to 40 mg/m 2, as measured by Cmax and AUC. No statistically significant difference between clearance values was shown for the 4 dose levels. The pharmacokinetics of docetaxel was not influenced by the coadministration of cisplatin on day 1 as compared to day 15, as the CmaxN, AUCN and CL were not statistically significantly different on both days. Fourteen patients were eva1uab1e for response, five cases achieved partial response, and thus the overall response was 35.7%. 1, 2, and 3 year survivals were 73%, 27%, and 20%, respectively. Weekly administration of docetaxel at 35mg/m 2 (days 1, 8, l5) combined with cisplatin 75mg/m 2 (day 1) is recommended for phase Ⅱ studies. Conclusions:Using the weekly schedule, toxicity was mainly manifested by non-hematologic profile and was well tolerated. A phase Ⅱ study is currently ongoing with docetaxel 35mg/m 2 as the suggested dosage.

18.
Article in Korean | WPRIM | ID: wpr-24519

ABSTRACT

PURPOSE: Patients with advanced ovarian carcinoma and refractory to platinum based chemotherapy have a very poor prognosis and effective salvage regimens are needed. This study was conducted in order to determine the maximum tolerated dose (MTD) and dose limiting toxicity of combination with paclitaxel and ifosfamide. MATERIALS AND METHODS: After premedication, patients received paclitaxel (110~225 mg/m2) as a 24 hour IV infusion on day 1. Ifosfamide (1,000~1,500 mg/m2) was given as a 12 hour IV infusion with standard dose of mesna on day 2~6. All patients received G-CSF (granulocyte colony stimulating factor) on day 6~15. RESULTS: 12 patients with advanced ovarian cancer entered this trial. Toxicity included bone marrow suppression, neuromuscular toxicity, urothelial toxicity, gastrointestinal toxicity, which occurred in 84.6%, 65.3%, 30.7%, 88.4% of cycles. CONCLUSION: Neuromuscular toxicity was dose limiting toxicity. Maximum tolerated dose in com bination with paclitaxel and ifosfamide was 175 mg/m2 of paclitaxel and 1,500 mg/m2 of ifosfamide.


Subject(s)
Humans , Bone Marrow , Drug Therapy , Granulocyte Colony-Stimulating Factor , Ifosfamide , Maximum Tolerated Dose , Mesna , Ovarian Neoplasms , Paclitaxel , Platinum , Premedication , Prognosis
19.
China Pharmacy ; (12)1991.
Article in Chinese | WPRIM | ID: wpr-528926

ABSTRACT

OBJECTIVE:To investigate the curative effect of metoprolol in treating chronic congestive heart failure (CCHF) and to discuss its administration technique.METHODS:A total of 72 patients with CCHF were randomly divided into treatment group and control group. The patients in the control group were treated with conventional therapy for heart failure,while those in the treatment group were treated with additional metoprolol at an initial dose of 6.25mg bid but gradually increased to 100mg bid for 24 weeks apart from the conventional therapy.RESULTS:The total responsive rate(RR) in the treatment group(88.9%) was significantly higher than in the control group(63.9%)(P

SELECTION OF CITATIONS
SEARCH DETAIL